Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02048384 · ClinicalTrials.gov registry record · Phase 1
A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02048384 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 22 participants.
The verdict
NCT02048384, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a phase 1b, multi-center, open label, randomized study to evaluate the safety and feasibility of administering metformin with or without rapamycin after disease stabilization on chemotherapy in subjects with metastatic PDA.
Interventions
- DRUG metformin alone (Arm A)
- DRUG metformin (Arm B)
- DRUG rapamycin (Arm B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-06-10 |
| Est. Completion | 2019-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02048384
The ClinicalTrials.gov registry entry for NCT02048384 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which metformin alone (Arm A) is the first listed.
NCT02048384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02048384 about?
NCT02048384 is a clinical study titled "A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer". This is a phase 1b, multi-center, open label, randomized study to evaluate the safety and feasibility of administering metformin with or without rapamycin after disease stabilization on chemotherapy in subjects with metastatic PDA.
What is the current status of trial NCT02048384?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2014-06-10. Estimated completion is 2019-09.
What interventions are being tested in trial NCT02048384?
The interventions under investigation include: metformin alone (Arm A) (DRUG), metformin (Arm B) (DRUG), rapamycin (Arm B) (DRUG).
Who is sponsoring clinical trial NCT02048384?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.